Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: Studies in isolated perfused hydronephrotic kidneys

R. Loutzenhiser, M. Epstein, K. Hayashi, T. Takenaka, H. Forster

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The renal microvascular effects of DuP 753, an orally active imidazole angiotensin II (ANG II) receptor antagonist were assessed directly in isolated perfused hydronephrotic rat kidneys. Unilateral hydronephrosis was induced to facilitate direct visualization of renal microvessels. Hydronephrotic kidneys were perfused in vitro and microvessel diameters were measured by automated computer-assisted image processing. The administration of 0.3 nmol/L ANG II decreased afferent arteriolar (AA) and efferent arteriolar (EA) diameters by 34 ± 3% (from 17.9 ± 0.6 to 11.9 ± 0.6 μm, P < .001, n = 11) and 28 ± 3% (from 17.1 ± 1.3 to 12.3 ± 1.3 μm, P < .001, n = 11), respectively. The subsequent administration of 0.1, 1.0, and 10 μmol/L DuP 753 reversed ANG II-induced vasoconstriction of the AA by 39 ± 10%, 81 ± 8%, and 103 ± 9%, and of the EA by 22 ± 7%, 51 ± 6%, and 87 ± 13%, respectively. These observations indicate that DuP 753 completely blocks both the renal afferent and efferent arteriolar actions of ANG II. In light of the pathogenetic role of ANG II in mediating the deranged renal hemodynamics associated with hypertension, conjestive heart failure, and some forms of renal insufficiency, our findings provide a theoretical framework for future studies assessing the potential therapeutic applicability of DuP 753 in reversing ANG II-mediated renal vasoconstriction.

Original languageEnglish
JournalAmerican Journal of Hypertension
Volume4
Issue number4 II SUPPL.
Publication statusPublished - 1991

Fingerprint

Losartan
Angiotensin II
Kidney
Microvessels
Vasoconstriction
Computer-Assisted Image Processing
Hydronephrosis
Angiotensin Receptor Antagonists
Renal Insufficiency
Heart Failure
Hemodynamics
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753 : Studies in isolated perfused hydronephrotic kidneys. / Loutzenhiser, R.; Epstein, M.; Hayashi, K.; Takenaka, T.; Forster, H.

In: American Journal of Hypertension, Vol. 4, No. 4 II SUPPL., 1991.

Research output: Contribution to journalArticle

@article{46b53469e9a943348164c4fedaad392e,
title = "Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: Studies in isolated perfused hydronephrotic kidneys",
abstract = "The renal microvascular effects of DuP 753, an orally active imidazole angiotensin II (ANG II) receptor antagonist were assessed directly in isolated perfused hydronephrotic rat kidneys. Unilateral hydronephrosis was induced to facilitate direct visualization of renal microvessels. Hydronephrotic kidneys were perfused in vitro and microvessel diameters were measured by automated computer-assisted image processing. The administration of 0.3 nmol/L ANG II decreased afferent arteriolar (AA) and efferent arteriolar (EA) diameters by 34 ± 3{\%} (from 17.9 ± 0.6 to 11.9 ± 0.6 μm, P < .001, n = 11) and 28 ± 3{\%} (from 17.1 ± 1.3 to 12.3 ± 1.3 μm, P < .001, n = 11), respectively. The subsequent administration of 0.1, 1.0, and 10 μmol/L DuP 753 reversed ANG II-induced vasoconstriction of the AA by 39 ± 10{\%}, 81 ± 8{\%}, and 103 ± 9{\%}, and of the EA by 22 ± 7{\%}, 51 ± 6{\%}, and 87 ± 13{\%}, respectively. These observations indicate that DuP 753 completely blocks both the renal afferent and efferent arteriolar actions of ANG II. In light of the pathogenetic role of ANG II in mediating the deranged renal hemodynamics associated with hypertension, conjestive heart failure, and some forms of renal insufficiency, our findings provide a theoretical framework for future studies assessing the potential therapeutic applicability of DuP 753 in reversing ANG II-mediated renal vasoconstriction.",
author = "R. Loutzenhiser and M. Epstein and K. Hayashi and T. Takenaka and H. Forster",
year = "1991",
language = "English",
volume = "4",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "4 II SUPPL.",

}

TY - JOUR

T1 - Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753

T2 - Studies in isolated perfused hydronephrotic kidneys

AU - Loutzenhiser, R.

AU - Epstein, M.

AU - Hayashi, K.

AU - Takenaka, T.

AU - Forster, H.

PY - 1991

Y1 - 1991

N2 - The renal microvascular effects of DuP 753, an orally active imidazole angiotensin II (ANG II) receptor antagonist were assessed directly in isolated perfused hydronephrotic rat kidneys. Unilateral hydronephrosis was induced to facilitate direct visualization of renal microvessels. Hydronephrotic kidneys were perfused in vitro and microvessel diameters were measured by automated computer-assisted image processing. The administration of 0.3 nmol/L ANG II decreased afferent arteriolar (AA) and efferent arteriolar (EA) diameters by 34 ± 3% (from 17.9 ± 0.6 to 11.9 ± 0.6 μm, P < .001, n = 11) and 28 ± 3% (from 17.1 ± 1.3 to 12.3 ± 1.3 μm, P < .001, n = 11), respectively. The subsequent administration of 0.1, 1.0, and 10 μmol/L DuP 753 reversed ANG II-induced vasoconstriction of the AA by 39 ± 10%, 81 ± 8%, and 103 ± 9%, and of the EA by 22 ± 7%, 51 ± 6%, and 87 ± 13%, respectively. These observations indicate that DuP 753 completely blocks both the renal afferent and efferent arteriolar actions of ANG II. In light of the pathogenetic role of ANG II in mediating the deranged renal hemodynamics associated with hypertension, conjestive heart failure, and some forms of renal insufficiency, our findings provide a theoretical framework for future studies assessing the potential therapeutic applicability of DuP 753 in reversing ANG II-mediated renal vasoconstriction.

AB - The renal microvascular effects of DuP 753, an orally active imidazole angiotensin II (ANG II) receptor antagonist were assessed directly in isolated perfused hydronephrotic rat kidneys. Unilateral hydronephrosis was induced to facilitate direct visualization of renal microvessels. Hydronephrotic kidneys were perfused in vitro and microvessel diameters were measured by automated computer-assisted image processing. The administration of 0.3 nmol/L ANG II decreased afferent arteriolar (AA) and efferent arteriolar (EA) diameters by 34 ± 3% (from 17.9 ± 0.6 to 11.9 ± 0.6 μm, P < .001, n = 11) and 28 ± 3% (from 17.1 ± 1.3 to 12.3 ± 1.3 μm, P < .001, n = 11), respectively. The subsequent administration of 0.1, 1.0, and 10 μmol/L DuP 753 reversed ANG II-induced vasoconstriction of the AA by 39 ± 10%, 81 ± 8%, and 103 ± 9%, and of the EA by 22 ± 7%, 51 ± 6%, and 87 ± 13%, respectively. These observations indicate that DuP 753 completely blocks both the renal afferent and efferent arteriolar actions of ANG II. In light of the pathogenetic role of ANG II in mediating the deranged renal hemodynamics associated with hypertension, conjestive heart failure, and some forms of renal insufficiency, our findings provide a theoretical framework for future studies assessing the potential therapeutic applicability of DuP 753 in reversing ANG II-mediated renal vasoconstriction.

UR - http://www.scopus.com/inward/record.url?scp=0025735453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025735453&partnerID=8YFLogxK

M3 - Article

C2 - 1854457

AN - SCOPUS:0025735453

VL - 4

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 4 II SUPPL.

ER -